Company: RGNT
Filing Date: 2025-01-24
Form Type: DRS
Source: 0001213900-25-006245
Chunk: 255

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-01-24
Form: DRS
Chunk 255
---
 | Between September 2004                                                                                                                    
 and December 2015, the Company received funding from the Israeli Innovation Authority (the “IIA”) for its participation                   
 in certain research and development activities, based on budgets approved by the IIA, subject to the fulfillment of specified milestones. 
 The Company is committed to pay royalties to the IIA on proceeds from sale of products related to research and development activities     
 of which the IIA participates by way of grants. According to the funding terms, royalties between 3% and 4.5% are payable on sales        
 of developed products funded, up to 100% of the grant received by the Company, linked to U.S. dollar and bearing Secured Overnight        
 Financing Rate (the “SOFR”) interest rate. In the case of failure of a funded research and development activity, the                      
 Company is not obligated to pay any such royalties to the IIA. As of June 30, 2024, total contingent obligation to IIA is at the          
 amount of $2,650 (including interest at the amount of $306).                                                                              |

| 2. | In February 2018, the Company                                                                                                      
 entered into a services agreement with Baxter Healthcare Corporation (the “Baxter Service Agreement” and “Baxter”,                 
 respectively), pursuant to which the Company agreed to purchase certain services from the third party in connection with GelrinC.  
 In April 2022, we amended the Baxter Services Agreement to replace Teva Medical Marketing Ltd. (“Teva”) as the supplier            
 of Tisseel under the Supply Agreement for GelrinC with Baxter Healthcare Distribution Ltd. as Teva ceased to distribute Tisseel in 
 the territory of Israel.                                                                                                           |

Under the Baxter Services Agreement,
Baxter provides the Company with quality, regulatory and technical support, for up to a maximum aggregate of 40 man-hours per year for
all such support.

<div align='center'>F-12</div>

REGENTIS BIOMATERIALS LTD.

NOTES TO THE UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

| NOTE 7:- | COMMITMENTS AND CONTINGENCIES (Cont.) |

In consideration for receiving such support,
the Company pays Baxter $60 per year until the Company will receive an approval from the U.S. Food and Drug Administration (“FDA”)
to market GelrinC in the United States. Following FDA approval to market GelrinC